Literature DB >> 15261850

TMS and drugs.

Ulf Ziemann1.   

Abstract

The application of a single dose of a CNS active drug with a well-defined mode of action on a neurotransmitter or neuromodulator system may be used for testing pharmaco-physiological properties of transcranial magnetic stimulation (TMS) measures of cortical excitability. Conversely, a physiologically well-defined single TMS measure of cortical excitability may be used as a biological marker of acute drug effects at the systems level of the cerebral cortex. An array of defined TMS measures may be used to study the pattern of effects of a drug with unknown or multiple modes of action. Acute drug effects may be rather different from chronic drug effects. These differences can also be studied by TMS measures. Finally, TMS or repetitive TMS by themselves may induce changes in endogenous neurotransmitters or neuromodulators. All these possible interactions are the focus of this in-depth review on TMS and drugs.

Mesh:

Substances:

Year:  2004        PMID: 15261850     DOI: 10.1016/j.clinph.2004.03.006

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  175 in total

1.  Post-stroke fatigue: a deficit in corticomotor excitability?

Authors:  Annapoorna Kuppuswamy; Ella V Clark; Isobel F Turner; John C Rothwell; Nick S Ward
Journal:  Brain       Date:  2014-11-02       Impact factor: 13.501

Review 2.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

3.  Cognitive function and cholinergic transmission in patients with subcortical vascular dementia and microbleeds: a TMS study.

Authors:  Raffaele Nardone; Pierpaolo De Blasi; Martin Seidl; Yvonne Höller; Francesca Caleri; Frediano Tezzon; Gunther Ladurner; Stefan Golaszewski; Eugen Trinka
Journal:  J Neural Transm (Vienna)       Date:  2011-04-24       Impact factor: 3.575

4.  Abnormal motor cortex excitability is associated with reduced cortical thickness in X monosomy.

Authors:  Jean-François Lepage; Cédric Clouchoux; Maryse Lassonde; Alan C Evans; Cheri L Deal; Hugo Théoret
Journal:  Hum Brain Mapp       Date:  2011-11-18       Impact factor: 5.038

Review 5.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

6.  Exploring the pathophysiology of mal de debarquement.

Authors:  Brian C Clark; Adam Quick
Journal:  J Neurol       Date:  2010-12-19       Impact factor: 4.849

7.  Neuronavigation increases the physiologic and behavioral effects of low-frequency rTMS of primary motor cortex in healthy subjects.

Authors:  S Bashir; D Edwards; A Pascual-Leone
Journal:  Brain Topogr       Date:  2010-11-13       Impact factor: 3.020

8.  Test-retest reliability of short-interval intracortical inhibition and intracortical facilitation in patients with schizophrenia.

Authors:  Xiaoming Du; L Elliot Hong
Journal:  Psychiatry Res       Date:  2018-06-19       Impact factor: 3.222

9.  Lamotrigine and valproic acid have different effects on motorcortical neuronal excitability.

Authors:  Xingbao Li; Raffaella Ricci; Charles H Large; Berry Anderson; Ziad Nahas; Mark S George
Journal:  J Neural Transm (Vienna)       Date:  2009-02-24       Impact factor: 3.575

10.  Online Transcranial Magnetic Stimulation Protocol for Measuring Cortical Physiology Associated with Response Inhibition.

Authors:  Michael D Guthrie; Donald L Gilbert; David A Huddleston; Ernest V Pedapati; Paul S Horn; Stewart H Mostofsky; Steve W Wu
Journal:  J Vis Exp       Date:  2018-02-08       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.